Enterprise Value
-35.39M
Cash
54.32M
Avg Qtr Burn
-9.767M
Short % of Float
0.51%
Insider Ownership
8.61%
Institutional Own.
17.78%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ONCT-808 (CAR-T) Details Solid tumor/s, Hematologic malignancies, Cancer | Phase 1/2 Data readout | |
ONCT-534 Details Cancer, Castration-resistant prostate cancer | IND Submission | |
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Paclitaxel Details Cancer, Metastatic breast cancer | Failed Discontinued | |
ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details Relapsed/refractory Ewing sarcoma, Cancer | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Cancer, Mantle cell lymphoma | Failed Discontinued |